Dr. Kelly Ross, MD
Claim this profileWest Virginia University Hospitals Inc
Studies Leukemia
Studies Myeloid Leukemia
4 reported clinical trials
11 drugs studied
Area of expertise
1Leukemia
t(8;21) negative
inv(16) negative
t(16;16) negative
2Myeloid Leukemia
t(8;21) negative
inv(16) negative
t(16;16) negative
Affiliated Hospitals
Clinical Trials Kelly Ross, MD is currently running
Pembrolizumab + TKI
for Chronic Myeloid Leukemia
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
Recruiting1 award Phase 2
Inotuzumab + Blinatumomab
for Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back, or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Recruiting1 award Phase 210 criteria
More about Kelly Ross, MD
Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Kelly Ross, MD has experience with
- Unlicensed CBU
- Gilteritinib
- Midostaurin
- Daunorubicin
- Cytarabine
- Pembrolizumab
Breakdown of trials Kelly Ross, MD has run
Leukemia
Myeloid Leukemia
Infusion Reaction
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kelly Ross, MD specialize in?
Kelly Ross, MD focuses on Leukemia and Myeloid Leukemia. In particular, much of their work with Leukemia has involved t(8;21) negative patients, or patients who are inv(16) negative.
Is Kelly Ross, MD currently recruiting for clinical trials?
Yes, Kelly Ross, MD is currently recruiting for 3 clinical trials in Morgantown West Virginia. If you're interested in participating, you should apply.
Are there any treatments that Kelly Ross, MD has studied deeply?
Yes, Kelly Ross, MD has studied treatments such as Unlicensed CBU, Gilteritinib, Midostaurin.
What is the best way to schedule an appointment with Kelly Ross, MD?
Apply for one of the trials that Kelly Ross, MD is conducting.
What is the office address of Kelly Ross, MD?
The office of Kelly Ross, MD is located at: West Virginia University Hospitals Inc, Morgantown, West Virginia 26506 United States. This is the address for their practice at the West Virginia University Hospitals Inc.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.